Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies

被引:145
作者
Flinn, IW
Byrd, JC
Morrison, C
Jamison, J
Diehl, LF
Murphy, T
Piantadosi, S
Seifter, E
Ambinder, RF
Vogelsang, G
Grever, MR
机构
[1] Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA
[2] Walter Reed Army Med Ctr, Washington, DC 20307 USA
关键词
D O I
10.1182/blood.V96.1.71.013k21_71_75
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To evaluate the response rate and potential toxicities, a phase II trial was conducted of fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated low grade and select intermediate grade lymphoid malignancies. Symptomatic patients with preserved end organ fu notion received cyclophosphamide 600 mg/m(2) intravenous (iv) day 1 and fludarabine 20 mg/m(2) iv days1 through 5, followed by filgrastim 5 mu g/kg subcutaneous starting approximately day 8. Treatment was repeated every 28 days until maximum response or a maximum of 6 cycles. Sixty patients, median age 53.5 years, were enrolled. Thirty-seven patients with non-Hodgkin lymphoma (NHL) were stage IV and 6 were stage ill, Eleven of 17 patients with chronic lymphocytic leukemia (CLL) were Rai intermediate risk end 6 were high risk. The overall complete response (CR) rate was 51% and the partial response (PR) rate was 41%. Of patients with CLL, 47% achieved a CR and the remaining 53% achieved a PR. Of patients with follicular lymphoma, 60% achieved CR and 32% achieved a PR. Although the toxicity of this regimen was mainly hematologic, significant nonhematologic toxicities, including infections, were seen. Twenty-four patients subsequently received an autologous or allogeneic stem cell transplant. Engraftment was rapid, and there were no noticeable procedure toxicities in the immediate posttransplant period attributable to the fludarabine and cyclophosphamide regimen. Fludarabine, cyclophosphamide, and filgrastim make up a highly active and well-tolerated regimen in CLL and NHL. (Blood. 2000;96:71-75) (C) 2000 by The American Society of Hematology.
引用
收藏
页码:71 / 75
页数:5
相关论文
共 28 条
  • [1] Herpes virus infections occur frequently following treatment with fludarabine: results of a prospective natural history study
    Byrd, JC
    McGrail, LH
    Hospenthal, DR
    Howard, RS
    Dow, NA
    Diehl, LF
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1999, 105 (02) : 445 - 447
  • [2] Byrd JC, 1998, SEMIN ONCOL, V25, P65
  • [3] Camitta BM, 1997, SEMIN ONCOL, V24, P83
  • [4] CARBONE PP, 1971, CANCER RES, V31, P1860
  • [5] GUIDELINES FOR CLINICAL PROTOCOLS FOR CHRONIC LYMPHOCYTIC-LEUKEMIA - RECOMMENDATIONS OF THE NATIONAL-CANCER-INSTITUTE-SPONSORED-WORKING-GROUP
    CHESON, BD
    BENNETT, JM
    RAI, KR
    GREVER, MR
    KAY, NE
    SCHIFFER, CA
    OKEN, MM
    KEATING, MJ
    BOLDT, DH
    KEMPIN, SJ
    FOON, KA
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 1988, 29 (03) : 152 - 163
  • [6] National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment
    Cheson, BD
    Bennett, JM
    Grever, M
    Kay, N
    Keating, MJ
    OBrien, S
    Rai, KR
    [J]. BLOOD, 1996, 87 (12) : 4990 - 4997
  • [7] ELIAS L, 1993, LEUKEMIA, V7, P361
  • [8] Flinn IW, 1997, BLOOD, V90, P2575
  • [9] High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission
    Freedman, AS
    Gribben, JG
    Neuberg, D
    Mauch, P
    Soiffer, RJ
    Anderson, KC
    Pandite, L
    Robertson, MJ
    Kroon, M
    Ritz, J
    Nadler, LM
    [J]. BLOOD, 1996, 88 (07) : 2780 - 2786
  • [10] HOCHSTER H, 1994, BLOOD, V84, pA383